Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01903330
Recruitment Status : Recruiting
First Posted : July 19, 2013
Last Update Posted : August 19, 2020
Sponsor:
Collaborators:
University of California, Irvine
Epitopoietic Research Corporation
Information provided by (Responsible Party):
Daniela A. Bota, University of California, Irvine

Brief Summary:
This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in treating patients with recurrent/progressive, bevacizumab naïve glioblastoma multiforme and gliosarcoma (World Health Organization (WHO) grade IV malignant gliomas, GBM).

Condition or disease Intervention/treatment Phase
Glioblastoma Gliosarcoma Drug: ERC1671 Drug: GM-CSF Drug: Cyclophosphamide Drug: Oral Control (Sucrose pill) Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)) Drug: Bevacizumab Phase 2

Detailed Description:

This is a blinded Phase II study of ERC1671 in combination with bevacizumab in patients with relapsed, bevacizumab naive glioblastoma. The patients who will be randomized (in a 1:1 ratio) to receive either ERC 1671 in combination with GM-CSF and cyclophosphamide or a placebo control, in combination with bevacizumab. The study will be double blinded.

ERC1671/GM-CSF will be intradermally administered, while cyclophosphamide is orally administered. GM-CSF dose is 500mcg fixed dose and cyclophosphamide dose is 50 mg/day. Bevacizumab is administered as standard of care at 10 mg/kg.

The treatment cycles will be 28 days long.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blinded, Placebo-controlled Study of (ERC1671/GM-CSF/Cyclophosphamide)+Bevacizumab vs. (Placebo Injection/Placebo Pill) +Bevacizumab in the Treatment of Recurrent/Progressive, Bevacizumab naïve Glioblastoma Multiforme and Glioasarcoma Patients (WHO Grade IV Malignant Gliomas, GBM)
Study Start Date : March 2014
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023


Arm Intervention/treatment
Experimental: (ERC1671/GM-CSF/Cyclophosphamide)+bevacizumab

ERC1671 and GM-CSF will be intradermally administered, while cyclophosphamide is orally administered. GM-CSF dose is 500mcg fixed dose and cyclophosphamide dose is 50 mg/day. Bevacizumab is administered as standard of care at 10 mg/kg.

The treatment will be repeated every 28 days until progression of disease or intolerance.

Drug: ERC1671
Given intradermally
Other Name: Gliovac

Drug: GM-CSF
Given intradermally
Other Names:
  • Leukine®
  • sargramostim

Drug: Cyclophosphamide
Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.
Other Name: 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Drug: Bevacizumab
Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
Other Name: Avastin

Placebo Comparator: (Placebo Injection/Placebo Pill) +Bevacizumab

The control group will have the same study schedule except that the patients will be receiving the Oral Control on the Cyclophosphamide treatment days and the Injectable control on the GM-CSF + ERC1671 treatment days. The control group will receive bevacizumab just as the active treatment group above.

The treatment will be repeated every 28 days until progression of disease or intolerance.

Drug: Oral Control (Sucrose pill)
Given PO

Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))
Given IV

Drug: Bevacizumab
Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
Other Name: Avastin




Primary Outcome Measures :
  1. Overall Survival at 12 months of patients with recurrent, bevacizumab naïve glioblastoma treated with ERC1671 in combination with GM-CSF and cyclophosphamide plus bevacizumab as compared with patients receiving bevacizumab plus placebo controls. [ Time Frame: 12 months ]
    To evaluate overall survival in patients with with recurrent, bevacizumab naïve glioblastoma treated with ERC1671 in combination with GM-CSF and cyclophosphamide plus bevacizumab as compared with patients receiving bevacizumab plus placebo controls.


Secondary Outcome Measures :
  1. Rate of Progression-Free Survival [ Time Frame: 12 months ]
    Progression-free survival will be defined as the time from Day 1 to the date of progression or death due to any cause.

  2. Immune Response [ Time Frame: 12 months ]
    The patient's immune response evaluation will include cytotoxic T lymphocytes (CTL) (CD3+/cluster of differentiation (CD)8+) and Treg (CD3+/CD4+/cluster of differentiation 25+ (CD25+)/CD127low) populations where CD refers to cluster of differentiation. Cytokine analyses should initially be limited to IFN-ɣ, TNF and IL-6. Further immune studies should include transforming growth factor (TGF)-B2, IL-12, IL-10.

  3. Percentage of Grade 3-5 Adverse Events [ Time Frame: 12 months ]
    Toxicity and adverse events are based on the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 4.0. Safety will also be assessed by clinical laboratory tests, physical examinations, vital sign measurements and the incidence and severity of adverse events (AEs).

  4. Rate of Radiographic Response as assessed using MacDonald Criteria or IRANO [ Time Frame: 12 month ]

    Patients will be followed both clinically and radiographically every 6 weeks for evidence of tumor progression. Tumor response will be assessed using the MacDonald Criteria or iRANO, Immunotherapy Response Assessment in Neuro-Oncology.

    iRANO/MacDonald CRITERIA:

    • Complete response (CR): Disappearance of all enhancing tumor on contrast enhanced MRI scan.
    • Partial response (PR): Greater than or equal to a 50% reduction in the size (sum of products of the largest diameter, SPD) for all enhancing lesions.
    • Stable Disease (SD): SPD <50% decrease to <25% increase, does not qualify for CR, PR, or progression.
    • Progressive Disease (PD): Greater than or equal to a 25% increase in SPD.
    • Unable to Assess (UA): Some target lesions cannot be evaluated because of technical factors.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

-Patients must have histologically confirmed diagnosis of a recurrent/progressive WHO grade IV malignant gliomas (glioblastoma multiforme and gliosarcoma) and meet the following inclusion criteria:

  1. Age ≥18 years of age.
  2. Histologic diagnosis of glioblastoma or gliosarcoma (WHO Grade IV).
  3. KPS of ≥ 70%.
  4. Life expectancy > 12 weeks.
  5. First or second relapse of glioblastoma.
  6. Previous treatment for glioblastoma must include surgery (biopsy, partial resection, or full surgical resection), conventional radiation therapy and temozolomide (TMZ).
  7. MRI record must be obtained showing the MRI was conducted at least 4 weeks after any salvage surgery, and at least 12 weeks after radiation therapy, or at least 4 weeks after radiation for a new lesion outside the prior primary radiation field unless relapse is confirmed by tumor biopsy or new lesion outside of radiation field, or if there are two MRIs confirming progressive disease per iRANO that are 8 weeks apart
  8. If prior therapy with gamma knife or other focal high-dose radiation, must have subsequent histologic documentation of local relapse, or relapse with new lesion outside the irradiated field.
  9. Resolution of all chemotherapy or radiation-related toxicities ≤ CTCAE Grade 1 severity, except for alopecia and hematologic toxicity. Patients taking temozolomide can start study treatment 23 days from the last temozolamide dose.For all other chemotherapy drugs, study treatment can start as long as all adverse events related to their prior treatment are no higher than Grade 1.
  10. Systemic corticosteroid therapy must be at a dose of ≤ 4 mg of dexamethasone or equivalent per day during the week prior to Day 1.
  11. Pre-surgical Bi-dimensionally measurable disease (as per iRANO criteria)
  12. Patients must have normal organ and marrow function as defined below:

    • hemoglobin (Hbg) > 9g/dL,
    • leukocytes >1,500/mcL
    • absolute neutrophil count>1,000/mcL
    • CD4 count > 450/mcL
    • platelets>125,000/mcL
    • Serum bilirubin = 1.5 × upper limit of normal (ULN) or = 3 x ULN if Gilbert's disease is documented AST(SGOT) and ALT(SGPT)<2.5 X institutional upper limit of normal
    • serum creatinine < 1.5 mg/dl
  13. Signed informed consent approved by the Institutional Review Board;
  14. If sexually active, patients must agree to take contraceptive measures for the duration of the treatments.

Exclusion Criteria:

  1. Subjects unable to undergo an MRI with contrast.
  2. Presence of diffuse leptomeningeal disease
  3. History, presence, or suspicion of metastatic disease
  4. Administration of immunosuppressive drugs less than 2 weeks prior to first dose of ERC1671, except dexamethasone for cerebral edema as detailed above;
  5. Prior receipt of bevacizumab or other VEGF- or VEGF receptor-targeted agents
  6. Known contraindication or hypersensitivity to any component of bevacizumab.
  7. Evidence of recent hemorrhage on screening MRI of the brain with the following exceptions: presence of hemosiderin; resolving hemorrhagic changes related to surgery; presence of punctate hemorrhage in the tumor.
  8. Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1.
  9. Evidence of bleeding diathesis or coagulopathy as documented by an elevated PT, PTT or bleeding time and clinically significant;
  10. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1.
  11. Urine protein: creatinine ratio ≥ 1.0 at screening;
  12. Anticipation of need for major surgical procedure during the course of the study.
  13. Serious non-healing wound, ulcer, or bone fracture.
  14. Active infection requiring treatment, known immunosuppressive disease, active systemic autoimmune diseases such as lupus, receipt of systemic immunosuppressive therapy, human immunodeficiency virus (HIV) infection, Hepatitis B or Hepatitis C
  15. Uncontrolled hypertension, blood pressure of > 150 mmHg systolic and > 100 mmHg diastolic, or history of hypertensive encephalopathy. Subjects with any known uncontrolled inter-current illness including ongoing or active infection, symptomatic congestive heart failure (NYHA Gr.2 or >), myocardial infarction, unstable angina pectoris , within the past 12 months
  16. Stroke, transient ischemic attack, unstable angina, myocardial infarction or congestive heart failure (New York Heart Association Grade II or greater) within the past 6 months.Unstable or severe intercurrent medical conditions chronic renal disease, or uncontrolled diabetes mellitus.
  17. Women who are pregnant or lactating. All female patients with reproductive potential must have a negative pregnancy test prior to Day 1 and must use a reliable form of contraception during study participation.
  18. Men refusing to exercise a reliable form of contraception.
  19. History of any malignancy (other than glioblastoma) during the last three years except non-melanoma skin cancer, in situ cervical cancer, treated superficial bladder cancer or cured, early-stage prostate cancer in a patient with Prostate Surface Antigen (PSA) level <ULN.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01903330


Locations
Layout table for location information
United States, California
University of California, Irvine Recruiting
Orange, California, United States, 92868
Contact: Chao Family Comprehensive Cancer Center University of California, Irvine Medical Center    877-827-8839    UCstudy@uci.edu   
Principal Investigator: Daniela A. Bota, MD, PhD         
United States, Massachusetts
Massachusetts General Hospital Cancer Center Recruiting
Boston, Massachusetts, United States, 02114
Contact: Justin Jordan, MD, MPH    855-986-9702    jtjordan@mgh.harvard.edu   
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: David Reardon, MD    877-338-7425    david_reardon@dfci.harvard.edu   
Sponsors and Collaborators
Daniela A. Bota
University of California, Irvine
Epitopoietic Research Corporation
Investigators
Layout table for investigator information
Principal Investigator: Daniela A. Bota, MD, PhD University of California, Irvine
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Daniela A. Bota, Principal Investigator, University of California, Irvine
ClinicalTrials.gov Identifier: NCT01903330    
Other Study ID Numbers: UCI 13-14 ERC1671-H02
UCI 13-14 ( Other Identifier: University of California, Irvine )
2013-9863 ( Other Identifier: University of California, Irvine )
First Posted: July 19, 2013    Key Record Dates
Last Update Posted: August 19, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Daniela A. Bota, University of California, Irvine:
ERC1671
GM-CSF
Cyclophosphamide
Bevacizumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Gliosarcoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Cyclophosphamide
Bevacizumab
Sargramostim
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Immunological
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors